Arsanis Biosciences is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infectious diseases, and is positioned to transform the course of patient outcomes and the growing global public health crisis of antibacterial resistance.

Arsanis Biosciences GmbH
Helmut-Qualtinger-Gasse 2/1
1030 Vienna
Austria
Building: MARXBOX – Map

+43 (0) 1 799 01 17